DexCom stock crashed after the company reported disappointing Q2 results and cut its full-year guidance. This performance raised questions about the potential impact of GLP-1 drugs on DexCom's ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous glucose monitor maker’s facilities last year. In a filing with the SEC, ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
DexCom reported a sales miss in the second quarter. (Courtesy DexCom) Shares of DexCom were spiraling after the medical device company surprised Wall Street with a steep cut to guidance, and grim news ...
Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...
Dexcom shares fell Thursday after the company released third-quarter results that beat expectations but showed slow revenue growth. The company's revenue increased 2% from $975 million a year earlier, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results